The Safety and Efficacy of Jobelyn in the Treatment of Breast Cancer Patients
Status:
Unknown status
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
To determine the effective functionality/potency of Jobelyn as an immunologic and
haematologic booster in Breast cancer patients (start-off), thus improving the outlook and
the quality of life of such patients generally